Last reviewed · How we verify

MYLAN SPECIALITY LP — Portfolio Competitive Intelligence Brief

MYLAN SPECIALITY LP pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Felbatol FELBAMATE marketed Anti-epileptic Agent [EPC] NMDA receptor-ionophore complex Neuroscience 1993-01-01
Soma CARISOPRODOL marketed Muscle Relaxant [EPC] Neuroscience 1959-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. Bausch Health · 1 shared drug class
  3. GSK · 1 shared drug class
  4. · 1 shared drug class
  5. Hikma · 1 shared drug class
  6. Johnson & Johnson · 1 shared drug class
  7. Generic (originally Abbott/AbbVie) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MYLAN SPECIALITY LP:

Cite this brief

Drug Landscape (2026). MYLAN SPECIALITY LP — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mylan-speciality-lp. Accessed 2026-06-10.

Related